论文部分内容阅读
30例诺和锐30血糖控制不满意患者,改为甘精胰岛素联合诺和锐30。结果12周后所有患者空腹血糖(治疗前9.34±2.15,治疗后5.37±1.26 mmol/L),接近正常上限,血糖波动小,糖血红蛋白HbA1c下降(治疗前8.19,1.38,治疗后7.21±0.72)症状性低血糖事件发生率明显减少。结论一部分应用诺和锐30治疗血糖控制不佳的患者,更改为甘精胰岛素联合诺和锐30治疗后可以获得良好的血糖控制。
30 cases Connaught Rui 30 blood glucose control not satisfied patients, replaced by glargine insulin and Nuo Rui 30. Results Fasting plasma glucose (before treatment 9.34 ± 2.15 and after treatment 5.37 ± 1.26 mmol / L) was close to the upper limit of normal, blood glucose fluctuation was small and HbA1c was decreased (8.19 and 1.38 before treatment and 7.21 ± 0.72 after treatment) The incidence of symptomatic hypoglycemia was significantly reduced. Conclusion Part of the application of Novo Rui 30 treatment of patients with poor blood glucose control, changed to insulin glargine and Novo-Rui 30 treatment can get good blood sugar control.